Home page A B C D E F G H I K L M N O P Q R S T U V W X Y Z

Ambien CR (zolpidem tartrate) dose, indications, adverse effects


Udocheals.orgAmbien drug
4.18.2017 | Jessica MacAdam
Ambien drug
Ambien CR (zolpidem tartrate) dose, indications, adverse effects

Administer as a single dose and do not re-administer during the same night. The 5 mg dose is recommended for debilitated adults. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Use the lowest effective dose. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Initially, 5 to 10 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg PO at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered.

Used for insomnia to aide in sleep initiation; some products may be used for middle-of-the night awakenings. Non-benzodiazepine hypnotic. Available in immediate and extended release formulations; rapid onset and short half-life reduces 'hangover' effects; does not cause early-AM awakening.

Separate multiple address with a comma.

Send the page " " to a friend, relative, colleague or yourself.

Max: 5 mg/day PO in residents meeting criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug. Use the lowest effective dose. 5 mg PO (1 spray into mouth and over the tongue) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. Avoid co-use with other sedative-hypnotics, including other zolpidem products. All sleep medications should be used in accordance with approved product labeling. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Administer as a single dose and do not be re-administer during the same night. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents.

A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Initially, 5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Use the lowest effective dose. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Administer as a single dose and do not re-administer during the same night. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects.

The 5 mg dose is recommended for debilitated adults. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Administer as a single dose and do not re-administer during the same night. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Initially, 5 to 10 mg PO (1 to 2 sprays in mouth over the tongue) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg (1 spray) at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Use the lowest effective dose.

Max: 12.5 mg/day PO at bedtime if needed; however, the higher dose is more likely to cause next-day impairment. Initially, 6.25 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Zolpidem should be taken as a single dose and should not be re-administered during the same night. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. The recommended dose for debilitated adults is 6.25 mg immediay before bedtime; these patients may be particularly sensitive to the effects of the drug. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Avoid co-use with other sedative-hypnotics, including other zolpidem products.

The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. A dose of 6.25 mg PO before bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. The recommended dose for debilitated adults is 6.25 mg immediay before bedtime; these patients may be particularly sensitive to the effects of the drug. Zolpidem should be taken as a single dose and should not be re-administered during the same night. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Max: 12.5 mg/day PO at bedtime if needed; however, the higher dose is more likely to cause next-day impairment. Avoid co-use with other sedative-hypnotics, including other zolpidem products. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Initially, 6.25 to 12.5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening.

Not a Member? Register Now this page.

Ambien CR/Zolpidem/Zolpidem Tartrate Oral Tab ER: 6.25mg, 12.5mg Ambien/Zolpidem/Zolpidem Tartrate Oral Tab: 5mg, 10mg Edluar/Intermezzo/Zolpidem/Zolpidem Tartrate Sublingual Tablet, SL: 1.75mg, 3.5mg, 5mg, 10mg Zolpimist Oropharyngeal Spray Met: 1actuation, 5mg.

The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents.Max: 5 mg/day PO in residents meeting the criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. Avoid co-use with other sedative-hypnotics, including other zolpidem products. 5 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. Geriatric patients and debilitated adults are particularly sensitive to the effects of zolpidem. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. Administer as a single dose and do not re-administer during the same night. Use the lowest effective dose. All sleep medications should be used in accordance with approved product labeling. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects.

3.5 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. A lower dose of 1.75 mg sublingually is recommended for males patients taking other CNS depressants. Avoid co-use with other sedative-hypnotics, including other zolpidem products, at bedtime or in the middle of the night. Use only if the patient has at least 4 hours of bedtime remaining before the planned time of waking. Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness.

We do not record any personal information entered above.

Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness. Daily dose thresholds are not available for zolpidem use in middle-of-the night awakenings; use in accordance with approved product labeling. Avoid co-use with other sedative-hypnotics, including other zolpidem products at bedtime or in the middle of the night. 1.75 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep. Use only when there are at least 4 hours of bedtime remaining before the planned time of waking. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. The 1.75 mg dose is also recommended for patients receiving a concomitant CNS depressant. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents.

Benzodiazepine Related Sedative/Hypnotics Rx, schedule IV. Your has been sent. Thank you.

If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. Use the lowest effective dose. All sleep medications should be used in accordance with approved product labeling. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. 5 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening. Avoid co-use with other sedative-hypnotics, including other zolpidem products. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. In residents meeting the criteria for treatment, Max: 5 mg/day PO in residents meeting the criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment, including effects on driving and performing other tasks requiring complete mental alertness. Administer as a single dose and do not be re-administer during the same night.

Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist.

Use the lowest effective dose. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. Initially, 5 mg PO (1 spray in mouth over the tonque) immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults. Administer as a single dose and do not re-administer during the same night. Avoid co-use with other sedative-hypnotics, including other zolpidem products. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem.

The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Administer as a single dose and do not re-administer during the same night. Initially, 5 to 10 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; 5 mg PO immediay before bedtime is the final dose recommended for debilitated adults. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. 5 mg PO at bedtime provides sufficient efficacy for many men, and this lower dosage should be considered. Avoid co-use with other sedative-hypnotics, including other zolpidem products. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. Use the lowest effective dose.

Avoid co-use with other sedative-hypnotics, including other zolpidem products. Patients should be cautioned regarding the risk of residual next-morning effects, and warned against engaging in hazardous activities, such as driving or other activities requiring complete mental alertness, the day after use until the patient is aware of how zolpidem affect them. Geriatric patients and debilitated adults may be particularly sensitive to the effects of the drug. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. All sleep medications should be used in accordance with approved product labeling. Max: 6.25 mg/day PO in residents meeting criteria for treatment, except when documentation is provided showing that higher doses are necessary to maintain or improve the resident's functional status. Zolpidem should be taken as a single dose and should not be re-administered during the same night. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. If the sleep agent is used routinely and is beyond the manufacturer's recommendations for duration of use, the facility should attempt a quarterly taper unless clinically contraindicated as defined in the OBRA guidelines. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of sedative/hypnotics in long-term care facility (LTCF) residents. 6.25 mg PO immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening.

Administer as a single dose and do not re-administer during the same night. The risk for next-morning impairment is higher if zolpidem is taken with less than a full night of sleep remaining (7 to 8 hours), if a higher than the recommended dose is taken, or if zolpidem is co-administered with other CNS depressants or drugs that increase the blood levels of zolpidem. Use the lowest effective dose. During concurrent use of a CNS depressant, dosage adjustments of zolpidem and the CNS depressant may be necessary because of the potential for additive effects. A full night of sleep (7 to 8 hours) is recommended to minimize the risk of next-day impairment. Avoid co-use with other sedative-hypnotics, including other zolpidem products. Max: 10 mg/day if needed; however, the higher dose is more likely to cause next-day impairment. Initially, 5 mg sublingually immediay before bedtime and with at least 7 to 8 hours remaining before the planned time of awakening; this is also the recommended dose for debilitated adults.

The 1.75 mg dose is also recommended for patients receiving a concomitant CNS depressant. Use only if the patient has at least 4 hours of bedtime remaining before the planned time of waking. The risk for next-morning impairment is higher if Intermezzo is taken with less than 4 hours of bedtime remaining, if a higher than the recommended dose is taken, or during co-administration with other CNS depressants or drugs that increase the blood levels of zolpidem. Avoid co-use with other sedative-hypnotics, including other zolpidem products at bedtime or in the middle of the night. Patients should be cautioned regarding the risk of residual next-morning effects, and instructed to wait for at least 4 hours after dosing and until they feel fully awake before driving or engaging in other activities requiring full mental alertness. 1.75 mg sublingually taken once per night if needed for a middle-of-the night awakening followed by difficulty returning to sleep.

Ambien drug